|
|
|
| Study on the Correlation between Serum Hcy and NT-pro-BNP and Clinical Prognosis of Patients with Chronic Heart Failure |
| HAI Lan, LEI Xiaoting, WANG Peng |
| Tianshui First People's Hospital, Gansu Tianshui 741000, China |
|
|
|
|
Abstract Objective: To explore the correlation between serum homocysteine (Hcy) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and clinical prognosis of patients with chronic heart failure (CHF). Methods: 70 cases of CHF patients admitted to department of cardiology of our hospital from January 2017 to March 2019 were included as observation group, and 70 healthy persons who came to the hospital for physical examination during the same period were selected as control group. The ultrasound detection indexes [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD)] and serum Hcy and NT-pro-BNP levels were compared between the two groups. Spearman correlation analysis was used to analyze the correlation between serum Hcy and NT-pro-BNP and LVEF and LVEDD. Patients in observation group were treated with anti-heart failure therapy. The occurrence of major adverse cardiovascular events (MACE) were followed up within 1 year after discharge. According to the follow-up results, the patients were divided into MACE group and non-MACE group, and the serum Hcy and NT-pro-BNP levels were compared between the groups. Results: The LVEF of observation group was less than that of control group while the LVEDD and serum Hcy, NT-pro-BNP were significantly higher than those of control group (all P<0.05). Spearman correlation analysis showed that serum Hcy and NT-pro-BNP were negatively correlated with LVEF (r=-0.867,-0.892, all P<0.05), and were positively correlated with LVEDD (r= 0.812, 0.870, all P<0.05). Serum Hcy and NT-pro-BNP of MACE group were significantly higher than those of non-MACE group (all P<0.05). Conclusion: Serum Hcy and NT Pro BNP levels are closely related to cardiac function in patients with CHF, which can provide basis for predicting clinical prognosis.
|
|
|
|
|
|
[1] 戎成振,卢家忠,王洪巨.慢性心力衰竭患者血浆copeptin、NT-proBNP表达变化的意义[J].山东医药,2018,58(1):49~51.
[2] 李三喜,吕杨,李涛.和肽素、血浆分化生长因子-15与NT-proBNP对心力衰竭患者早期诊断价值研究[J].川北医学院学报,2017,32(1):112~115.
[3] 刘钟应,黄洁,黄建凤.射血分数正常的中重度心衰患者血压变异性和N端脑钠肽前体的关系[J].中国分子心脏病学杂志,2018,18(1):2356~2359.
[4] 姚国库,王书强,张志方.血清PHT联合NT-proBNP检测对急性心衰患者的诊断效果分析[J].中国实验诊断学,2019,23(4):92~95.
[5] 史钰芳,陈士金,王庆海,等.NT-proBNP与CysC对慢性心力衰竭患者心功能及左室重构的影响[J].心脑血管病防治,2017,17(2):119~121.
[6] 何巧,黄勇.左心衰竭患者血清MR-ProANP、NT-ProBNP含量与泵血功能、心室重构的相关性研究[J].海南医学院学报,2017,23(2):201~204,208.
[7] 赵世明.rhBNP应用对行PCI术后并发心力衰竭AMI病人心脏功能、NT-proBNP水平及死亡率的影响[J].中西医结合心脑血管病杂志,2018,16(6):760~762.
[8] 甄根深,张奇峰,刘威,等.hs-cTnI及NT-proBNP最佳截断值与慢性心衰患者生存期的相关性研究[J].中国循证心血管医学杂志,2019,11(4):106~108,112.
[9] Pan Y , Li D , Ma J ,et al.NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure[J].Medicine,2017,96(51):e9181.
[10] Sato M , Sakata Y , Oikawa T , et al. Prognosis and prognostic factors of elderly patients with chronic heart failure-a report from the CHART-2 study[J]. Journal of Cardiac Failure, 2017, 23(10):S80.
[11] Lu X , Mao Y . ECONOMIC evaluation of Nt-probnp guided therapy in patients with chronic heart failure[J]. Value in Health,2017,20(9):A572. |
|
|
|
2020, Vol. 26 
